医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Survey of degree of satisfaction with Agaricus blazei mushroom KA21 for promoting the health of senior dogs and cats among veterinarians and pet owners, Toei Shinyaku

2022年08月12日 PM01:00
このエントリーをはてなブックマークに追加


 

TOKYO

A survey was conducted with veterinarians and pet owners concerning the degree of satisfaction with the effects of Agaricus blazei mushroom, KA21 strain as a supplement for pets (dogs and cats), for improvement of the appetite, coat & amount of fur, and amount of exercise among senior dogs and cats. The survey found that the degree of satisfaction was in the range of 86.5 – 94.4 percent among the veterinarians and 85.7 – 94.7 percent among the owners. Agaricus blazei, KA21 strain product also being sold as a supplement for pets within Japan, and is supported by many veterinarians and pet owners.

About Agaricus blazei, brasiliensis, subrufescens

Agaricus blazei (also known as A. blazei Murill, A. brasiliensis, A. subrufescens) is a medicinal mushroom. It is popular primarily in Asian countries (particularly Japan) as an ingredient of immune booster used in complementary and alternative medicine (CAM). Characteristics of Agaricus blazei such as safety and effectiveness vary significantly depending on the strain, cultivation method, and production region.

Agaricus KA21 (Common name: King Agaricus)

Agaricus KA21 is Agaricus blazei KA21 strain cultivated outdoors in Brazil under direct sunlight. Compared to regular Agaricus blazei cultivated in a dark greenhouse, Agaricus KA21 is large in size, contains an abundance of major ingredients such as beta-glucan and vitamin D, and offers an antioxidant activity level over five times greater. Outdoor cultivation is extremely difficult with small yield, therefore Agaricus KA21 is a rare commodity. Toei Shinyaku is the sole company in the world that sells it.

Toei Shinyaku Co.,Ltd.

Established in 1973, Toei Shinyaku is a Japanese manufacturer that specializes in R&D activities, as well as the manufacture and sale of Agaricus KA21. Toei Shinyaku has conducted research on Agaricus KA21 for over 25 years and presented 32 international papers on its findings; making it the company with the greatest research results out of all Japanese Agaricus blazei manufacturers. Toei Shinyaku discloses evidence supporting its product, Agaricus KA21, on its official homepage. Details include the safety of human clinical trials of Agaricus KA21, ability to strengthen the immune system, alleviate fatigue, improve hair loss and gray hair, and prevent fungal infection. Data also includes the effect of Agaricus KA21 found through trials on mice; such as reducing side effects of anticancer drugs, hair growth benefits, and enhanced wound healing.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220807005051/en/

CONTACT

Toei Shinyaku Co.,Ltd.

Akitomo Motoi

info@toeishinyaku.jp

Cross-Border EC website: www.toeishinyaku.jp

For business inquiry including wholesales and OEM: www.agaricus.co.jp

Main Products: Akkerman Slim etc.

同じカテゴリーの記事 

  • MHRA Issues Notice of Acceptance for POLARIS-AD, a Phase 3 Early Alzheimer’s Disease Trial Sponsored by AriBio Co., Ltd.
  • Celltrion在第19届ECCO大会上公布了皮下注射英夫利西单抗(CT-P13 SC)治疗炎症性肠病(IBD)的两年新数据
  • セルトリオン、第19回 ECCO会議で炎症性腸疾患(IBD)における皮下インフリキシマブ(CT-P13 SC)の2年間の新データを発表
  • Neuraptive Therapeutics, Inc. 公布了NTX-001在2期NEUROFUSE研究中表现积极的24周数据,强化了之前宣布的概念验证12周数据结果
  • ニューラプティブ・セラピューティクス、NTX-001に関する第2相NEUROFUSE研究における24週間の良好なデータを発表し、以前に発表した概念実証の12週間データを補強